# Phreesia share price today (Phreesia, Inc., PHR)

> Phreesia, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. PHR · Healthcare · Health Information Services · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/phr

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $12.23 (−46.0% in a year)
- P/E: 71.2×, against its own history
- Revenue (Jul 2026): $129 M (+10.4% on a year ago)
- Profit (Jul 2026): $1.9 M (+193.3% on a year ago)
- Operating margin: 5.9% (+7.2 points on a year ago)
- ROE: 1%, FY26

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Phreesia share price today? Phreesia, Inc.'s share price was $12.23 at the close on 3 November 2026. It has been stalling near its high for 3 weeks. That is 12.4% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. In the last 52 weeks it traded between $8 and $22, and at that close it sat 30% of the way up from that low. Over the last 7.3 years the share price moved −49% while the S&P 500 moved +154%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Phreesia pay? Phreesia, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Phreesia on? Phreesia is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Phreesia profitable? Phreesia, Inc. earned $1.9 M of net profit in the Jul 2026 quarter, +193.3% on the same quarter a year earlier. Full-year FY26 profit was $2.3 M. That is 1.5% of the quarter's revenue. The same quarter a year earlier earned $654 K. 7 of the last 12 reported quarters were loss-making. ## How much revenue does Phreesia make, and is it growing? Phreesia, Inc. reported $129 M of revenue in the Jul 2026 quarter, +10.4% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 22.5% a year on average. The last full year, FY26, came in at $481 M. The last four reported quarters add to $508 M. FY26 revenue was $481 M, +14.5% on the year before. Recent pace: the last four quarters grew +13.0% on average, against 22.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +12.9%, against +14.1% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Phreesia keep? Phreesia, Inc.'s operating margin was 5.9% in the Jul 2026 quarter, 7.2 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −62.9% and 0.5%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +7.2 percentage points on the year while gross margin changed −1.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Phreesia's profit turning into cash? Phreesia, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY26 it brought in $78.8 M of operating cash against $2.3 M of profit. After $11.1 M of spending on assets, $67.7 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Phreesia's cash go? Phreesia, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $25.6 M on assets over the last 3 years. Averaged over those years that is 1.8% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $25.6 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Phreesia's P/E ratio, and how does it compare with its own history? Phreesia, Inc.'s P/E is 71.2×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Phreesia business getting better or worse? Phreesia, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Phreesia earn on its capital? Phreesia, Inc. earned a ROE of 1% in FY26. That is up from a low of −61% in FY23. Its return on capital used (ROIC) is 4.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 0.5% net margin and 0.72× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 0.5% net margin × 0.72× asset turnover × 1.97× leverage (assets divided by equity) ≈ 0.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 3.6% − 8.5% = −4.9 percentage points. The 8.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Phreesia have too much debt? Phreesia, Inc. has total debt of $67.9 M against shareholder equity of $372 M as of Jul 2026, so its debt is 0.18× its equity, which is very little. Year by year, that ratio went from 0.04 in FY22 to 0.30 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Phreesia shareholding pattern? 6.3% of Phreesia, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Phreesia from balance-sheet trouble? For Phreesia, Inc., the Z-score is 1.51. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.51 is inside the danger zone, so the balance sheet is a real risk. ## How does Phreesia rank in its industry? 47.9 out of 100, rank 10 of 29 in Health Information Services, with 67% of the evidence available. Phreesia, Inc. scores 47.9 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 10. Earnings are strong; relative strength in its sector is -26.7% and the one-year return is -44.5%. The four parts add up to the total exactly: 23.7 + 9.5 + 9 + 5.7 = 47.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Phreesia compared with? Phreesia ranks 10 of 29 Health Information Services companies on the 4-Factor Sector Score, with 47.9 out of 100. 1. [Hinge Health, Inc.](https://www.sectoralpha.in/us/stocks/hnge) HNGE · leader · Most evidence points up · 64% evidence 72.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.5/35 · Revenue 49.7% · Profit n/a · Operating margin change 436.5 points · 62% evidence Capital efficiency 19.0/25 · ROCE 27.1% · Operating margin 19% · 76% evidence Valuation 9.3/20 · P/E 59.8× · PEG n/a · 15% evidence Relative strength 17.7/20 · Lead over its industry 42% · Lead over S&P 500 75.7% · 1 year 162.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.5 + 19 + 9.3 + 17.7 = 72.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Veeva Systems Inc.](https://www.sectoralpha.in/us/stocks/veev) VEEV · breaking out · Most evidence points up · 85% evidence 69.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 16.5% · Profit 25.2% · Operating margin change 0.9 points · 95% evidence Capital efficiency 18.8/25 · ROCE 13.6% · Operating margin 29.6% · 76% evidence Valuation 13.0/20 · P/E 32.6× · PEG 1.3 · 65% evidence Relative strength 16.9/20 · Lead over its industry 6.4% · Lead over S&P 500 33.9% · 1 year 2.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.9 + 18.8 + 13 + 16.9 = 69.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [HeartFlow, Inc.](https://www.sectoralpha.in/us/stocks/htfl) HTFL · leader · Evidence leans up · 61% evidence 57.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 43.2% · Profit n/a · Operating margin change 3.7 points · 62% evidence Capital efficiency 4.5/25 · ROCE -24.2% · Operating margin -27.9% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 19.2/20 · Lead over its industry 23.6% · Lead over S&P 500 54.5% · 1 year 67.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 4.5 + 10 + 19.2 = 57.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Waystar Holding Corp.](https://www.sectoralpha.in/us/stocks/way) WAY · breaking out · Evidence leans up · 81% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 19.4% · Profit 58.8% · Operating margin change 0.4 points · 83% evidence Capital efficiency 12.2/25 · ROCE 5.2% · Operating margin 24.4% · 76% evidence Valuation 15.6/20 · P/E 29.2× · PEG 0.64 · 65% evidence Relative strength 8.0/20 · Lead over its industry -20.2% · Lead over S&P 500 2% · 1 year -23.6% · 100% evidence · 11 of 12 weeks ahead Exact sum: 19.7 + 12.2 + 15.6 + 8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Schrödinger, Inc.](https://www.sectoralpha.in/us/stocks/sdgr) SDGR · leader · Evidence leans up · 64% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 8.8% · Profit n/a · Operating margin change 26 points · 62% evidence Capital efficiency 4.6/25 · ROCE -32.9% · Operating margin -70.6% · 76% evidence Valuation 11.2/20 · P/E -22.3× · PEG n/a · 15% evidence Relative strength 18.5/20 · Lead over its industry 22.6% · Lead over S&P 500 53% · 1 year 52.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 4.6 + 11.2 + 18.5 = 55.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [HealthEquity, Inc.](https://www.sectoralpha.in/us/stocks/hqy) HQY · quiet · Evidence leans up · 85% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 7.4% · Profit 62.3% · Operating margin change 0.5 points · 95% evidence Capital efficiency 16.1/25 · ROCE 11.4% · Operating margin 28.4% · 76% evidence Valuation 11.6/20 · P/E 35.6× · PEG 1.53 · 65% evidence Relative strength 6.1/20 · Lead over its industry -15.9% · Lead over S&P 500 7.3% · 1 year 8.9% · 100% evidence · 5 of 12 weeks ahead Exact sum: 21.4 + 16.1 + 11.6 + 6.1 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BrightSpring Health Services, Inc.](https://www.sectoralpha.in/us/stocks/btsg) BTSG · turning · Too little evidence to rank firmly · 56% evidence 53.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.0/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 39% evidence Capital efficiency 12.6/25 · ROCE 10.1% · Operating margin 3.4% · 76% evidence Valuation 10.0/20 · P/E 39.7× · PEG n/a · 15% evidence Relative strength 11.3/20 · Lead over its industry 2.2% · Lead over S&P 500 29.7% · 1 year 110.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 20 + 12.6 + 10 + 11.3 = 53.9 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. [Doximity, Inc.](https://www.sectoralpha.in/us/stocks/docs) DOCS · breaking out · Evidence leans up · 81% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.5/35 · Revenue 11.2% · Profit -28.6% · Operating margin change -16.3 points · 83% evidence Capital efficiency 20.9/25 · ROCE 21.6% · Operating margin 21.5% · 76% evidence Valuation 10.8/20 · P/E 22.7× · PEG 1.74 · 65% evidence Relative strength 9.8/20 · Lead over its industry -17.6% · Lead over S&P 500 5.1% · 1 year -40% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11.5 + 20.9 + 10.8 + 9.8 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Tempus AI, Inc.](https://www.sectoralpha.in/us/stocks/tem) TEM · breaking out · Evidence leans up · 64% evidence 51.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.1/35 · Revenue 50.2% · Profit n/a · Operating margin change -0.6 points · 62% evidence Capital efficiency 5.6/25 · ROCE -14.3% · Operating margin -19.6% · 76% evidence Valuation 11.4/20 · P/E -40.9× · PEG n/a · 15% evidence Relative strength 14.4/20 · Lead over its industry -1.4% · Lead over S&P 500 25% · 1 year 8.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.1 + 5.6 + 11.4 + 14.4 = 51.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. Phreesia, Inc. this page PHR · turning · Evidence leans down · 67% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 12.7% · Profit n/a · Operating margin change 7.2 points · 71% evidence Capital efficiency 9.5/25 · ROCE 4.3% · Operating margin 5.9% · 76% evidence Valuation 9.0/20 · P/E 63.5× · PEG n/a · 15% evidence Relative strength 5.7/20 · Lead over its industry -26.7% · Lead over S&P 500 -6.1% · 1 year -44.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.7 + 9.5 + 9 + 5.7 = 47.9 · What this means: Earnings are strong; relative strength in its sector is -26.7% and the one-year return is -44.5%. 11. [NRC Health](https://www.sectoralpha.in/us/stocks/nrc) NRC · turning · Evidence leans down · 64% evidence 47.7 out of 100 Growth Capital Valuation Relative
12. [Certara, Inc.](https://www.sectoralpha.in/us/stocks/cert) CERT · leader · Evidence leans down · 64% evidence 46.4 out of 100 Growth Capital Valuation Relative
13. [HealthStream, Inc.](https://www.sectoralpha.in/us/stocks/hstm) HSTM · leader · Evidence leans down · 81% evidence 46.2 out of 100 Growth Capital Valuation Relative
14. [Spok Holdings, Inc.](https://www.sectoralpha.in/us/stocks/spok) SPOK · turning · Evidence leans down · 81% evidence 46.1 out of 100 Growth Capital Valuation Relative
15. [American Well Corporation](https://www.sectoralpha.in/us/stocks/amwl) AMWL · losing its lead · Evidence leans down · 61% evidence 45.2 out of 100 Growth Capital Valuation Relative
16. [10x Genomics, Inc.](https://www.sectoralpha.in/us/stocks/txg) TXG · leader · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
17. [Omada Health, Inc.](https://www.sectoralpha.in/us/stocks/omda) OMDA · quiet · Evidence leans down · 64% evidence 44.9 out of 100 Growth Capital Valuation Relative
18. [Privia Health Group, Inc.](https://www.sectoralpha.in/us/stocks/prva) PRVA · basing · Evidence leans down · 81% evidence 43.0 out of 100 Growth Capital Valuation Relative
19. [Omnicell, Inc.](https://www.sectoralpha.in/us/stocks/omcl) OMCL · basing · Evidence leans down · 71% evidence 42.7 out of 100 Growth Capital Valuation Relative
20. [Carlsmed, Inc.](https://www.sectoralpha.in/us/stocks/carl) CARL · breaking out · Evidence leans down · 61% evidence 41.2 out of 100 Growth Capital Valuation Relative
21. [Teladoc Health, Inc.](https://www.sectoralpha.in/us/stocks/tdoc) TDOC · turning · Evidence leans down · 61% evidence 41.2 out of 100 Growth Capital Valuation Relative
22. [Claritev Corporation](https://www.sectoralpha.in/us/stocks/ctev) CTEV · quiet · Evidence leans down · 64% evidence 37.4 out of 100 Growth Capital Valuation Relative
23. [SOPHiA GENETICS SA](https://www.sectoralpha.in/us/stocks/soph) SOPH · losing its lead · Evidence leans down · 61% evidence 37.1 out of 100 Growth Capital Valuation Relative
24. [Evolent Health, Inc.](https://www.sectoralpha.in/us/stocks/evh) EVH · turning · Evidence leans down · 64% evidence 36.9 out of 100 Growth Capital Valuation Relative
25. [GoodRx Holdings, Inc.](https://www.sectoralpha.in/us/stocks/gdrx) GDRX · quiet · Most evidence points down · 81% evidence 33.9 out of 100 Growth Capital Valuation Relative
26. [Simulations Plus, Inc.](https://www.sectoralpha.in/us/stocks/slp) SLP · Too little evidence to rank firmly · 44% evidence 56.3 out of 100 Growth Capital Valuation Relative
27. [Talkspace, Inc.](https://www.sectoralpha.in/us/stocks/talk) TALK · Too little evidence to rank firmly · 44% evidence 48.4 out of 100 Growth Capital Valuation Relative
28. [Weave Communications, Inc.](https://www.sectoralpha.in/us/stocks/weav) WEAV · Too little evidence to rank firmly · 41% evidence 47.7 out of 100 Growth Capital Valuation Relative
29. [TruBridge, Inc.](https://www.sectoralpha.in/us/stocks/tbrg) TBRG · Too little evidence to rank firmly · 31% evidence 42.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Health Information Services](https://www.sectoralpha.in/us/sectors/health-information-services), all 29 compared on one page. ## Which companies are close to Phreesia in size? Phreesia is the 19th largest of 30 Health Information Services companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Omada Health, Inc., HealthStream, Inc. and Talkspace, Inc. Just below it: Weave Communications, Inc., SOPHiA GENETICS SA and NRC Health. ### Health Information Services companies close in size

1. [Omada Health, Inc.](https://www.sectoralpha.in/us/stocks/omda) $1.1 billion
2. [HealthStream, Inc.](https://www.sectoralpha.in/us/stocks/hstm) $969 million
3. [Talkspace, Inc.](https://www.sectoralpha.in/us/stocks/talk) $871 million
4. Phreesia, Inc. $759 million
5. [Weave Communications, Inc.](https://www.sectoralpha.in/us/stocks/weav) $592 million
6. [SOPHiA GENETICS SA](https://www.sectoralpha.in/us/stocks/soph) $588 million
7. [NRC Health](https://www.sectoralpha.in/us/stocks/nrc) $511 million

[All 30 Health Information Services companies, largest first](https://www.sectoralpha.in/us/sectors/health-information-services#all-companies)

### Companies close in size in other industries

1. [Fidus Investment Corporation](https://www.sectoralpha.in/us/stocks/fdus) $775 million · Asset Management
2. [Azul S.A.](https://www.sectoralpha.in/us/stocks/azul) $773 million · Airlines
3. Phreesia, Inc. $772 million
4. [Collegium Pharmaceutical, Inc.](https://www.sectoralpha.in/us/stocks/coll) $771 million · Drug Manufacturers - Specialty & Generic
5. [Playtika Holding Corp.](https://www.sectoralpha.in/us/stocks/pltk) $770 million · Electronic Gaming & Multimedia

## What else do people ask about Phreesia? ### What were Phreesia's latest quarterly results? Phreesia, Inc. reported revenue of $129 M and net profit of $1.9 M for the Jul 2026 quarter. Revenue rose 10.4% and profit rose 193.3% compared with a year earlier. Earnings per share were $0.03. The operating margin was 5.9%, 7.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is Phreesia's market cap? Phreesia, Inc.'s market capitalisation is $759 M at a stock price of $12.23. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Phreesia performing? Phreesia, Inc.'s share price has been stalling near its high for 3 weeks. In its latest quarter, revenue rose 10.4% and profit rose 193.3% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running (as of 3 November 2026). ### Will Phreesia's stock price go up? This page does not forecast Phreesia, Inc.'s stock price. What it shows instead: the stock price is $12.23, and it has been stalling near its high for 3 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Phreesia in its business cycle? Phreesia, Inc.'s FY26 operating margin was 0.5%, against a 5-year range of −62.9% to 0.5%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 5.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Phreesia story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Phreesia a stock worth studying right now? What the numbers show: Phreesia, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.